Form 4: Kymera Therapeutics Director Booth Bruce Sells Shares Under 10b5-1 Trading Plan

Director Booth Bruce of Kymera Therapeutics sold shares of common stock on June 12 and 13, 2024, under pre-arranged Rule 10b5-1 trading plans.

Summary

• Booth Bruce, a director at Kymera Therapeutics, executed multiple sales of common stock on June 12 and 13, 2024.
• The sales were conducted under Rule 10b5-1 trading plans adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
• On June 12, 2024, 11,838 shares were sold at a weighted average price of $35.35, and 1,997 shares were sold at a weighted average price of $36.02.
• An additional 2,485 shares were sold at $35.35 and 420 shares were sold at $36.02 on June 12, 2024.
• On June 13, 2024, 8,430 shares were sold at a weighted average price of $34.98, and 1,770 shares were sold at the same price.
• The shares are held indirectly through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with the reporting person disclaiming beneficial ownership except to the extent of his pecuniary interest.
• Following these transactions, the reporting person indirectly holds 4,548,400 shares through Atlas Venture Fund X, L.P. and 802,022 shares through Atlas Venture Opportunity Fund I, L.P.

Sentiment

Score: 5

Explanation: The document is neutral as it simply reports transactions. The sales are under a pre-arranged plan, so they don't necessarily indicate a negative outlook.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any forward-looking statements regarding the company's future performance.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-arranged. The pharmaceutical industry is often subject to insider trading scrutiny due to the potential for material non-public information related to drug development and regulatory approvals.

Comparison to Industry Standards

• It's common for directors and officers of publicly traded companies, including those in the biotechnology sector like Amgen (AMGN) or Gilead Sciences (GILD), to have pre-arranged trading plans to sell shares.
• The volume of shares sold is relatively small compared to the total outstanding shares of Kymera Therapeutics.
• Similar to other venture-backed companies, directors affiliated with venture capital firms like Atlas Venture often have structured plans for gradually liquidating their holdings.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sales mitigates this concern.

Key Dates